Atara Biotherapeutics redirected its focus toward its pipeline of treated donor cell therapies in the second half of 2019, while it continues its search to fill three top roles. The shift in priority was the first sign of a company “going all in” on an allogeneic treatment for multiple sclerosis, said Salim Syed, senior biotech…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
